Caroline Helwick

1 week ago | ascopost.com | Caroline Helwick

According to the initial findings of an ongoing first-in-human phase I trial, reported at the European Hematology Association (EHA) 2025 Congress, promising results have been shown for a novel off-the-shelf tri-specific antibody in the treatment of patients with multiple myeloma highly refractory to other therapies (Abstract S100).

1 week ago | ascopost.com | Caroline Helwick

Prevention of graft-vs-host disease (GVHD) was superior with a cyclophosphamide/cyclosporin-based regimen compared with standard prophylaxis in patients receiving a matched-sibling donor stem cell transplant in a large Australian randomized trial, investigators reported at the European Hematology Association (EHA) 2025 Congress (Abstract S103). The study, which may ultimately change the standard of care, was published simultaneously in The New England Journal of Medicine.

1 week ago | ascopost.com | Caroline Helwick

Combining polatuzumab vedotin-piiq with rituximab, gemcitabine, and oxaliplatin (Pola–R-GemOx) significantly improved survival outcomes in patients with transplant-ineligible, relapsed or refractory diffuse large B-cell lymphoma (DLBCL) over standard R-GemOx alone, in the phase III POLARGO trial.

2 weeks ago | ascopost.com | Caroline Helwick

“Inavolisib plus palbociclib and fulvestrant significantly improved overall survival compared with placebo plus palbociclib/fulvestrant…. This is the first time overall survival has been significantly improved by a PI3K pathway–targeted drug,” said Nicholas Turner, MD, PhD, FRCP,FMedSci, who reported the results at a press briefing ahead of the 2025 ASCO Annual Meeting. Dr. Turner is Director of Clinical Research and Development at the Royal Marsden Hospital and Institute of Cancer in London.

2 weeks ago | ascopost.com | Caroline Helwick

In the phase III ALASCCA trial, the use of adjuvant daily aspirin for 3 years reduced the risk of recurrence in colorectal cancer harboring PI3K pathway alterations by 51%, according to research in a Scandinavian population presented at the 2025 ASCO Gastrointestinal Cancers Symposium by Anna Martling, MD, PhD, of the Karolinska Institutet and Karolinska University Hospital in Stockholm.1 Dr. Martling estimated that implementation of daily aspirin “could change clinical practice for around...